5-Amino-1MQ and GLP-1 fatigue: what the science actually shows

What did @glpeptides actually say?

Honestly? Not much. The transcript from this video is entirely unintelligible, consisting of repeated syllables with no actual spoken claims. The caption, however, makes a specific assertion: that 5-Amino-1MQ "helps overcome the energy loss commonly experienced when using GLP-1 medications." That caption claim is what we're fact-checking here, because it's what viewers read and act on.

This is worth noting upfront: when a creator's caption makes a health claim but the video itself contains no supporting explanation, no mechanism, no caveats, and no sourcing, that's a pattern worth being skeptical about. The claim floats free of any context.

Does the science back this up?

The evidence for 5-Amino-1MQ in humans is essentially nonexistent. The compound is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular energy metabolism and fat storage. In theory, blocking NNMT could raise NAD+ availability and improve mitochondrial function. In practice, the human data isn't there yet.

The most cited work comes from Neelakantan et al. (2018, Journal of Medicinal Chemistry), which showed NNMT inhibition reduced fat mass in diet-induced obese mice. Subsequent rodent studies have shown some metabolic improvements. But mice are not people, and no peer-reviewed human trials of 5-Amino-1MQ have been published as of 2024. The leap from "this worked in obese mice" to "this fixes your GLP-1 fatigue" is not a small one. It's a canyon.

GLP-1 receptor agonists like semaglutide do cause fatigue in a subset of users, likely tied to caloric restriction, nausea, and muscle loss rather than a single metabolic bottleneck that NNMT inhibition would cleanly fix.

What did they get wrong (or right)?

The caption claim is misleading, not because the underlying mechanism is implausible, but because it's stated as settled fact when the human evidence doesn't exist. Saying a compound "helps overcome" a clinical symptom implies demonstrated efficacy. That bar has not been cleared for 5-Amino-1MQ in humans.

What they got directionally right: fatigue and energy loss are real, documented complaints among GLP-1 users, and NNMT inhibition is a legitimate area of metabolic research. The biological rationale isn't nonsense. But biological rationale is not the same as clinical evidence, and conflating the two is how people end up spending money on compounds with no proven benefit in their actual situation.

The video also makes no mention of the regulatory status of 5-Amino-1MQ. It is not FDA-approved for any indication. It is sold as a research chemical. Presenting it as a solution to a side effect of a regulated medication, without any of that context, is a meaningful omission.

What should you actually know?

If you're on a GLP-1 medication and experiencing energy loss, the causes are likely multifactorial. Significant caloric deficit, reduced protein intake, muscle mass loss (sarcopenia), and GI side effects are all documented contributors. Addressing those through adequate protein consumption, resistance training, and working with your prescriber is supported by actual clinical evidence.

Lean mass preservation during GLP-1 therapy is a real clinical concern. Wilding et al. (2021, New England Journal of Medicine) and subsequent STEP trial analyses showed meaningful lean mass reduction alongside fat loss in semaglutide users. Strategies like higher protein intake and resistance training have evidence behind them. 5-Amino-1MQ does not, at least not in humans yet.

NNMT research is genuinely interesting and worth watching. But "interesting preclinical research" and "take this to fix your GLP-1 fatigue" are two very different statements, and this video's caption collapses that distinction entirely.

Bottom line

The claim in this caption runs ahead of the evidence by a significant margin. If 5-Amino-1MQ human trials emerge and show benefit for fatigue in GLP-1 users, that would be worth revisiting. Right now, the honest answer is: we don't know if it works in people. Anyone telling you otherwise is speculating, whether they know it or not.